SYED ZAIDI: Open Payments
NPI 1932549250 · FRIENDSWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$486 in 15 payments from 10 companies in 2025. Trend: 2023 $1,448 · 2024 $120 · 2025 $486
Food & beverage: $486
| Company | Payments | Amount |
|---|---|---|
| ABIOMED | 1 | $186 |
| UCB, Inc. | 2 | $55 |
| ACADIA Pharmaceuticals Inc | 2 | $44 |
| Alkermes, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| SK Life Science, Inc. | 1 | $26 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
Products named: Bimzelx, NUPLAZID, ARISTADA, COBENFY, INGREZZA, UZEDY, ERZOFRI EXTENDED-RELEASE, REXULTI.
Industry payments across TX — which companies pay providers there.
